Join
Live feed
·
PRReleasevia Quantisnow
BlackRock Technology and Private Equity Term Trust logo

Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

ByQuantisnow·Wall Street's wire, on your screen.
BTX· BlackRock Technology and Private Equity Term Trust

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BTX (BlackRock Technology and Private Equity Term Trust) and more on Quantisnow.